Literature DB >> 3749228

Quantitative analysis of naloxone antagonism of the discriminative stimulus properties of morphine in the pigeon.

W D Wessinger, D E McMillan.   

Abstract

Pigeons were trained to discriminate morphine (5.0 mg/kg) from saline under a second-order fixed ratio 10 (fixed-ratio 5) color-tracking schedule for food reinforcement. After reliable stimulus control was established, cumulative graded doses of morphine (0.3-30.0 mg/kg) were tested and resulted in dose-dependent increases in morphine-appropriate key pecking and decreases in response rate. Cumulative doses of naloxone (0.1-10.0 mg/kg) or consecutive injections of saline did not elicit morphine-appropriate responding or affect response rate. Pre-treatment with naloxone (0.1-1.0 mg/kg) before determination of cumulative dose-effect curves for morphine caused the morphine generalization curves to be shifted, in a parallel manner, rightward. Dose-ratio analysis of naloxone antagonism of morphine generalization, using a Schild plot with the slope constrained to -1, gave an apparent pA2 value (95% confidence limits) of 6.53 (6.18-6.89).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3749228     DOI: 10.1016/0091-3057(86)90254-6

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  3 in total

1.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987.

Authors:  I P Stolerman; F Rasul; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Effects of nimodipine on the discriminative stimulus properties of d-amphetamine in rats.

Authors:  P Nencini; W L Woolverton
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

3.  Pharmacological analysis of the rate-decreasing effects of mu and kappa opioids in pigeons.

Authors:  A J Mattox; M J Picker; L A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  1994-01       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.